Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05353647 · ClinicalTrials.gov registry record · Phase 2
A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)
A Phase 2 study of Sickle Cell Disease, sponsored by David Williams.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 9
- Study locations
NCT05353647 is a Phase 2 study of Sickle Cell Disease that is active but no longer recruiting, run by David Williams. The registered enrollment target is 25 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The trial reports 9 study locations across 5 states.
The verdict
NCT05353647, a Phase 2 study of Sickle Cell Disease, is active but no longer recruiting, sponsored by David Williams.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 9
- Study locations
Study Summary
A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine in which genetic material (mostly DNA) in the patient is changed to treat his or her own disease. In gene therapy, we introduce new genetic material in order to fix or replace the patient's disease gene, with the goal of curing the disease. The procedure is similar to a bone marrow transplant, in that the patient's malfunctioning blood stem cells are reduced or eliminated using chemotherapy, but it is different because instead of using a different person's (donor) blood stem cells for the transplant, the patient's own blood stem cells are given back after the new genetic material has been introduced into those cells. This approach has the advantage of eliminating any risk of graft versus host disease (GVHD), reducing the risk of graft rejection, and may also allow less chemotherapy to be utilized for the conditioning portion of the transplant procedure. To introduce new genetic material into the patient's own blood stem cells we use a modified version of a virus (called a 'vector') that efficiently inserts the "correcting" genetic material into the cells. The vector is a specialized biological medicine that has been formulated for use in human beings. Fetal hemoglobin (HbF) is a healthy, non-sickling kind of hemoglobin. The investigators have discovered a gene that is very important in controlling the amount of HbF. Decreasing the expression of this gene in sickle cell patients could increase the amount of fetal hemoglobin while simultaneously reducing the amount of sickle hemoglobin in their blood, specifically the amount in red blood cells where sickle hemoglobin causes damage to the cell, and therefore potentially cure or significantly improve the condition. The gene we are targeting for change in this study that controls the level of fetal hemoglobin is called BCL11A. In summary, the advantages of a gene therapy approach include
Conditions Studied
Interventions
- BIOLOGICAL Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Study Locations (9)
California
- Children's Hospital of Los Angeles - Los Angeles
- UCLA Medical Center - Los Angeles
- UCSF Benioff Children's Hospital Oakland - Oakland
- UC Davis Medical Center - Sacramento
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute/Brigham and Women's Hospital - Boston
Georgia
- Children's Healthcare of Atlanta/Emory University - Atlanta
Illinois
- Lurie Children's Hospital of Chicago - Chicago
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2022-07-12 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05353647
The ClinicalTrials.gov registry entry for NCT05353647 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (91% lower). The listed sponsor is David Williams, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a is the first listed.
NCT05353647 reports 9 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, Georgia.
Frequently Asked Questions
What is clinical trial NCT05353647 about?
NCT05353647 is a clinical study titled "A Gene Transfer Study Inducing Fetal Hemoglobin in Sickle Cell Disease (GRASP, BMT CTN 2001)". A promising approach for the treatment of genetic diseases is called gene therapy. Gene therapy is a relatively new field of medicine in which genetic material (mostly DNA) in the patient is changed to treat his or her own disease. In gene therapy, we introduce new genetic material in order to fix o...
What is the current status of trial NCT05353647?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2022-07-12. Estimated completion is 2027-07.
What conditions does trial NCT05353647 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT05353647?
The interventions under investigation include: Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a (BIOLOGICAL).
Who is sponsoring clinical trial NCT05353647?
This trial is sponsored by David Williams, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05353647 being conducted?
This trial has 9 study locations across California, Georgia, Illinois, Massachusetts, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.